Safety of intravitreally delivered AAV2 vector‐mediated multi‐characteristic opsin genetic construct in wild type beagle dogs
Authors:
- 23 July 2024
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 26 (7) , e3720
Abstract
Background: A novel adeno‐associated virus 2 (AAV2)‐carried multi‐characteristic opsin (MCO) (MCO‐010) is undergoing several clinical trials as a novel therapeutic modality for the treatment of degenerative retinal diseases including retinitis pigmentosa and Stargardt disease. The present study aimed to determine the ocular and systemic safety of MCO‐010 and the AAV2 vehicle in adult Beagle dogs following intravitreal (IVT) injection.Methods: The current safety/toxicology studies spanning 13 weeks described here utilized well‐documented techniques to assess the effects of IVT injection of MCO‐010 up to 2.2 × 1011 genome copies (gc) per eye, or the AAV2 capsid (vehicle control) on gross behavioral and immunogenic changes, alterations in body weights, blood biochemistry, hematology, blood coagulation, gross necropsy lesions, organ weight changes and histopathology in the dogs (n = 4 per group; two males and two females per group). Immunohistochemical and functional electroretinogram studies were also conducted to determine MCO expression in the retina and determine any retinal toxicity associated with MCO‐010.Results: There were no significant deleterious effects of the MCO‐010 (or the AAV2 at the tested doses) on any of the examined parameters, including the absence of any severe ocular or systemic adverse events. However, as expected, inflammation after IVT delivery of AAV2 and MCO‐010 was observed in the conjunctivae of all groups of animals, although this self‐resolved within 1 week post‐injection. Quantitative immunohistochemical analyses of MCO‐010‐associated mCherry revealed successful delivery of the gene therapy within the inner retina.Conclusions: In summary, MCO‐010 demonstrated a favorable safety profile when administered to the eyes of adult Beagle dogs of both sexes at dose levels up to 2.2 × 1011 gc per eye, with no adverse effects observed. This dose was identified as the No Observed Adverse Effect Level (i.e. NOAEL) and guided selection of safe doses for human clinical trials.Keywords
Funding Information
- National Eye Institute (1R01EY025717‐01A1, 2R44EY025905‐02A1)
This publication has 30 references indexed in Scilit:
- Gene therapies and gene product-based drug candidates for normalizing and preserving tissue functions in animal models of ocular hypertension and glaucomaMolecular Aspects of Medicine, 2023
- Identifying new drugs and targets to treat rapidly elevated intraocular pressure for angle closure and secondary glaucomas to curb visual impairment and prevent blindnessExperimental Eye Research, 2023
- Immune responses to retinal gene therapy using adeno-associated viral vectors – Implications for treatment success and safetyProgress in Retinal and Eye Research, 2021
- Effect of inhalation anesthesia with isoflurane on circadian rhythm of murine intraocular pressureExperimental Eye Research, 2021
- Dog as a model in studies on human hereditary diseases and their gene therapyReproductive Biology, 2014
- Clinical and Genetic Characteristics of Late-onset Stargardt's DiseaseOphthalmology, 2012
- Monocyte Modulation of Aqueous Outflow and Recruitment to the Trabecular Meshwork Following Selective Laser TrabeculoplastyArchives of Ophthalmology (1950), 2010
- Channelrhodopsin-2 gene transduced into retinal ganglion cells restores functional vision in genetically blind ratsExperimental Eye Research, 2010
- Ectopic Expression of a Microbial-Type Rhodopsin Restores Visual Responses in Mice with Photoreceptor DegenerationNeuron, 2006
- Rod bipolar cells in the mammalian retina show protein kinase C‐like immunoreactivityJournal of Comparative Neurology, 1990